Guidance: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics

TitleGuidance: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics
ToC Doc Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics
Docket Number2022-13606
Type Notice
Subject Guidance:
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics
Publication Date2022-06-27
Last Updated Date 2022-06-24 08:15:08 -0400
Last Public Inspection2022-06-24
Filed At2022-06-24T08:45:00.000-04:00
PDF 2022-13606_PI.pdf (104093 bytes)
Download TXT / HTML / JSON
Number of Pages 5
Filing Typeregular
AgenciesFood and Drug Administration

You can find the raw source document below...

This site's data is aggregated programmatically and provided "as is" without any representations or warranties, express or implied. OFR.report is not affiliated with the Office of the Federal Register or the US government in any way.

© OFR.report 2021